Navigation Links
Maturitas publishes 2013 update on diagnosis and management of osteoporosis
Date:6/19/2013

Amsterdam, June 19, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of the National Osteoporosis Guideline Group (NOGG) Update 2013 on diagnosis and management of osteoporosis in postmenopausal women and older men in the journal Maturitas.

Published in 2009 in Maturitas, the original guidelines have been highly cited and this update is timely with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. In all these areas, there have been new developments over the past few years that have had an impact on clinical practice and require modifications and/or additions to previous guidance.

The recommendations in the guidelines are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice.


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Page: 1

Related medicine news :

1. Maturitas publishes a clinical guide on lichen sclerosus
2. Journal Maturitas publishes position statement on diet and health in midlife and beyond
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. Zane Benefits Publishes New Information on Health Reimbursement Accounts
5. Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses
6. Zane Benefits Publishes New Information on California Exchange Rates
7. Zane Benefits Publishes New Information for Small Businesses on Health Insurance
8. Zane Benefits Publishes New Information on Maine Health Insurance Exchange
9. Zane Benefits Publishes New Information on Small Businesses Health Insurance Requirements in 2014
10. Zane Benefits Publishes New Information on Health Reimbursement Arrangements
11. Zane Benefits Publishes New Information on Health Reimbursement Arrangements for Small Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: